权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

NCTN Lead Academic Participating Site at Dana-Farber/Partners Cancer Care

NCTN 在 Dana-Farber/Partners Cancer Care 的主要学术参与网站

基本信息

批准号：
10358570
负责人：
Harold John Burstein
金额：
$ 110.91万
依托单位：
DANA-FARBER CANCER INST
依托单位国家：
美国
项目类别：
财政年份：
2019
资助国家：
美国
起止时间：
2019-03-05 至 2025-02-28
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10358570
关键词：
Adherence Adult American American College of Radiology Imaging Network Americas Awareness Biometry Breast Cancer Burden Cancer Patient Caring Clinical Clinical Research Clinical Treatment Clinical Trials Clinical Trials Cooperative Group Colorectal Committee Membership Communities Conduct Clinical Trials Dana-Farber Cancer Institute Development Discipline Disease Eastern Cooperative Oncology Group Enrollment Ensure Funding Future General Hospitals Generations Goals Grant Head and neck structure Hospitals Infrastructure Institution Lead Leadership Lung Malignant Neoplasms Malignant neoplasm of lung Malignant neoplasm of ovary Malignant neoplasm of prostate Massachusetts Medical Mentors Mission Modality Modeling Monitor Multiple Myeloma National Cancer Institute National Clinical Trials Network Oncology Operative Surgical Procedures Patient-Focused Outcomes Patients Pilot Projects Positioning Attribute Principal Investigator Prostate Protocols documentation Radiation therapy Research Research Personnel Role Scientific Advances and Accomplishments Site Societies Support Groups Supportive care Symptoms Teaching Hospitals Time Training Translational Research Translations Woman Work anticancer research base cancer care cancer therapy cancer type clinical trial implementation cohesion design experience experimental study fight against imaging modality imaging study improved improved outcome innovation leukemia malignant breast neoplasm melanoma member multimodality novel pre-clinical programs rare cancer sarcoma standard care support network treatment trial trial design tumor

项目摘要

Project Summary This grant supports Network Lead Academic Participating Site (NLAPS) at Dana-Farber/Partners Cancer Care – a community of investigators and clinicians committed to reduce the burden of cancer in American society by contributing scientific leadership and patient accrual to the National Clinical Trials Network (NCTN) activities of the National Cancer Institute. Dana-Farber/Partners Cancer Care includes three of Harvard's major teaching hospitals – Dana-Farber Cancer Institute, Brigham & Women's Hospital, and Massachusetts General Hospital – and the grant supports the cancer researchers and clinicians based at those hospitals. This community of investigators and clinicians has a remarkable track record of leadership in the NCTN including executive leaders of cooperative groups, investigators heading national trials, and researchers who develop pilot studies and preclinical experiments that lead to definitive, practice-defining clinical trials in the NCTN. The NLAPS also has a tremendous record of robust accrual to NCTN trials. Notably, the scientific and accrual contributions cover the full spectrum of cancer need in the US, including major cancer types (breast, lung, prostate, colorectal, and others) as well as less common but important cancers (head and neck, melanoma, leukemia, multiple myeloma, sarcoma and others), and all modalities of cancer treatment including medical therapies, radiation treatments, surgery, biostatistical design, translational science, and innovations in symptom control and supportive care for cancer patients. Recent scientific advances that emerged from DF/PCC leadership in the NCTN include new treatment standards in prostate cancer, breast cancer, leukemia, and melanoma. The NLAPS grant is vital to the mission of DF/PCC and allows its investigators to offer cutting edge treatments to patients through innovative studies that will define the future of cancer care in America.

项目概要这笔赠款支持 Dana-Farber/Partners Cancer Care 的网络领导学术参与站点 (NLAPS) – 一个由研究人员和临床医生组成的社区，致力于通过以下方式减轻美国社会的癌症负担为国家临床试验网络 (NCTN) 活动贡献科学领导力和患者获益美国国家癌症研究所。 Dana-Farber/Partners Cancer Care 包括哈佛大学的三个主要教学内容医院 – 达纳法伯癌症研究所、布莱根妇女医院和麻省总医院 – 这笔赠款支持这些医院的癌症研究人员和临床医生。这个社区的研究人员和临床医生在 NCTN 中拥有出色的领导记录，包括执行官合作小组的领导者、领导国家试验的研究人员以及开展试点研究的研究人员以及在 NCTN 中进行明确的、定义实践的临床试验的临床前实验。国家拉普斯还拥有 NCTN 试验的强劲应计记录。值得注意的是，科学性和权责发生制捐款涵盖了美国所有癌症需求，包括主要癌症类型（乳腺癌、肺癌、前列腺癌、结直肠癌等）以及不太常见但重要的癌症（头颈癌、黑色素瘤、白血病、多发性骨髓瘤、肉瘤等）以及所有癌症治疗方式，包括药物治疗疗法、放射治疗、手术、生物统计设计、转化科学和创新癌症患者的症状控制和支持护理。最近出现的科学进展 DF/PCC 在 NCTN 中的领导地位包括前列腺癌、乳腺癌、白血病、和黑色素瘤。 NLAPS 拨款对于 DF/PCC 的使命至关重要，并使其研究人员能够提供切割服务通过创新研究为患者提供边缘治疗，这将定义美国癌症护理的未来。